Literature DB >> 25468562

Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells.

Juan Shan1, Li Feng2, Guixiang Sun2, Peng Chen2, Yanni Zhou2, Mengjuan Xia2, Hongsheng Li2, Youping Li3.   

Abstract

BACKGROUND: Immune response outcome, inflammation or tolerance, often depends on the balance between regulatory T cells (Tregs) and effective T cells (Teffs). Rapamycin (Rapa) has been reported to selectively expand Tregs and promote de novo generation of foxp3(+) Tregs, suggesting its potential role in inducing tolerance. But the mechanism by which Rapa regulating the Treg-Teff balance is yet to be understood.
METHODS: Mouse CD4(+)CD25(-) Teffs and CD4(+)CD25(+) Tregs are sorted by MACS. These T cell subsets were labeled with CFSE and cultured with anti-CD3/CD28 Ab±IL-2 for 6 days. Two rounds of stimulation of 3 days each were performed. Rapa or Jak Inhibitor I was added to the culture when indicated. Cells were harvested after each round of stimulation. CFSE dilution, FOXP3, miR-155 expression and the signaling via the mTOR and STAT5 pathways were determined. And miR-155-mimic and miR-155-antagomir were transfected into purified CD4(+) T cells respectively to detect miR-155 role in regulating STAT5 signaling.
RESULTS: Firstly, we confirmed that the effect of Rapa on proliferating T cells is time-dependent: it reduces both Teffs and Tregs proliferation at early stage, but selectively promotes Tregs proliferation after second round of stimulation. Then we found there is direct interaction between mTOR and STAT5 signaling, and this interaction explained the time-dependent effect of Rapa and may participate in deciding Teff-Treg balance: mTOR inhibition up-regulated the expression of phos-STAT5 in both proliferating Tregs and Teffs via miR-155. And foxp3 is the down streaming target of phos-STAT5, thus Rapa could maintain expanded Tregs function and promote de novo generation of foxp3(+) Tregs. However, the phos-4E-BP1 expression pattern is different in proliferating Tregs and Teffs. 4E-BP1 is the common target of mTOR and STAT5 signaling, and plays a key role in cell proliferation. Rapa inhibits phos-4E-BP1 expression in both Tregs and Teffs at early stage of proliferation, but selectively raises its expression in Tregs after second round of stimulation. This may explains why Rapa inhibits Teffs growth, but delays Tregs proliferation.
CONCLUSION: Together, these findings indicate that the dynamic interaction between mTOR and STAT5 signaling modulates the reciprocal differentiation of the effective and regulatory T cells, and differently affect their proliferation activity. This provides a new insight of how Treg-Teff balance is regulated.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Immune balance; MicroRNA-155; Rapamycin; Regulatory T cell; STAT5 signaling; mTOR signaling

Mesh:

Substances:

Year:  2014        PMID: 25468562     DOI: 10.1016/j.imbio.2014.10.020

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  14 in total

1.  High frequency of central memory regulatory T cells allows detection of liver recipients at risk of early acute rejection within the first month after transplantation.

Authors:  Francisco Boix-Giner; Olga Millan; David San Segundo; Pedro Muñoz-Cacho; Esther Mancebo; Santiago Llorente; Lourdes Rafael-Valdivia; Antoni Rimola; Emilio Fábrega; Anna Mrowiec; Luis Allende; Alfredo Minguela; Jose M Bolarín; Estela Paz-Artal; Marcos López-Hoyos; Mercé Brunet; Manuel Muro
Journal:  Int Immunol       Date:  2015-08-12       Impact factor: 4.823

2.  mTORC1 signaling is crucial for regulatory T cells to suppress macrophage-mediated inflammatory response after acute myocardial infarction.

Authors:  Keping Yang; Yunfeng Zhang; Chenhong Xu; Xin Li; Dazhu Li
Journal:  Immunol Cell Biol       Date:  2015-10-06       Impact factor: 5.126

3.  PO-322 exerts potent immunosuppressive effects in vitro and in vivo by selectively inhibiting SGK1 activity.

Authors:  Yi Lai; Xing-Yan Luo; Hui-Jie Guo; Si-Yu Wang; Jing Xiong; Shu-Xia Yang; Li-Mei Li; Qiang Zou; Chun-Fen Mo; Yan-Tang Wang; Yang Liu
Journal:  Br J Pharmacol       Date:  2020-02-11       Impact factor: 8.739

Review 4.  Regulatory T Cells and Kidney Transplantation.

Authors:  Paloma Leticia Martin-Moreno; Sudipta Tripathi; Anil Chandraker
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-22       Impact factor: 8.237

Review 5.  Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells.

Authors:  Nicholas A Zwang; Joseph R Leventhal
Journal:  J Am Soc Nephrol       Date:  2017-05-02       Impact factor: 10.121

6.  Notch-1 Inhibition Promotes Immune Regulation in Transplantation Via Regulatory T Cell-Dependent Mechanisms.

Authors:  Ciara N Magee; Naoka Murakami; Thiago J Borges; Tetsunosuke Shimizu; Kassem Safa; Shunsuke Ohori; Songjie Cai; Audrey Uffing; Jamil Azzi; Wassim Elyaman; Louis-Marie Charbonnier; Kaifeng Liu; Demet Toprak; Gary Visner; Talal A Chatila; Christian W Siebel; Nader Najafian; Leonardo V Riella
Journal:  Circulation       Date:  2019-07-03       Impact factor: 29.690

Review 7.  Dynamic Roles for IL-2-STAT5 Signaling in Effector and Regulatory CD4+ T Cell Populations.

Authors:  Devin M Jones; Kaitlin A Read; Kenneth J Oestreich
Journal:  J Immunol       Date:  2020-10-01       Impact factor: 5.422

8.  Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis.

Authors:  Hsin-Yuan Cheng; Dalia E Gaddis; Runpei Wu; Chantel McSkimming; LaTeira D Haynes; Angela M Taylor; Coleen A McNamara; Mary Sorci-Thomas; Catherine C Hedrick
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

9.  Phloretin Modulates Human Th17/Treg Cell Differentiation In Vitro via AMPK Signaling.

Authors:  Ao Jiao; Zhaoming Yang; Xibo Fu; Xiangdong Hua
Journal:  Biomed Res Int       Date:  2020-07-29       Impact factor: 3.411

Review 10.  The Role of Immune Modulation in Pathogenesis of IgA Nephropathy.

Authors:  Sheng Chang; Xiao-Kang Li
Journal:  Front Med (Lausanne)       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.